Kallmann syndrome (KS), defined by the association of hypogonadotropic hypogonadism and anosmia or hyposmia, can be caused by mutations in the KAL gene on Xp 22.3. This gene encodes an extracellular matrix glycoprotein called anosmin-1, which belongs to the class of cell adhesion molecules. In the absence of a functional KAL protein, migration of both olfactory and gonadotropin-releasing hormone neurons is arrested. A defective anosmin-1 molecule may also play a role in the development of synkinesia and renal agenesis, which are exclusively seen in the X-linked form of KS. We describe the clinical presentation and molecular diagnosis of the defect in two brothers with KS. An X-linked mode of transmission was assumed on the basis of synkinesia and the presence of oligomenorrhoea in the mother. A novel nonsense mutation was found in exon 13 of the KAL gene, encoding the region of the fourth fibronectin type III repeat of anosmin-1, which results in an apparently nonfunctional truncated protein.

Keywords:
Kallmann syndrome, KAL gene, Anosmin-1, Hypogonadotropic hypogonadism, KAL gene mutation
1.
Kallmann FJ, Schoenfeld WA, Barrera SE: The genetic aspects of primary eunuchoidism. Am J Ment Defic 1944;48:203–236.
2.
De Morsier G: Etudes sur les dysraphies cranioencéphaliques. I. Agénésie des lobes olfactifs (télencéphaloschizis latéral) et des commissures calleuses et antérieures (télencéphaloschizis médian): La dysplasie olfacto-génitale. Schweiz Arch Neurol Psychiatr 1954;74:309–361.
3.
Georgopoulos NA, Pralong FP, Seidman CE, Seidman JG, Crowley WF Jr, Vallejo M: Genetic heterogeneity evidenced by low incidence of KAL-1 gene mutations in sporadic cases of gonadotropin-releasing hormone deficiency. J Clin Endocrinol Metab 1997;82:213–217.
4.
Waldstreicher J, Seminara SB, Jameson JL, Geyer A, Nachtigall LB, Boepple PA, Holmes LB, Crowley WF Jr: The genetic and clinical heterogeneity of gonadotropin-releasing hormone deficiency in the human. J Clin Endocrinol Metab 1996;81:4388–4395.
5.
Hermanussen M, Sippell WG: Heterogeneity of Kallmann’s syndrome. Clin Genet 1985;28:106–111.
6.
White BJ, Rogol AD, Brown KS, Lieblich JM, Rosen SW: The syndrome of anosmia with hypogonadotropic hypogonadism: A genetic study of 18 new families and a review. Am J Med Genet 1983;15:417–435.
7.
Franco B, Guioli S, Pragliola A, Incerti B, Bardoni B, Tonlorenzi R, Carrozzo R, Maestrini E, Pieretti M, Taillon-Miller P, Brown CJ, Willard HF, Lawrence C, Persico MG, Camerino G, Ballabio A: A gene deleted in Kallmann’s syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 1991;353:529–536.
8.
Legouis R, Hardelin J-P, Levilliers J, Claverie J-M, Compain S, Wunderle V, Millasseau P, Le Paslier D, Cohen D, Caterina D, Bougueleret L, Delemarre-van de Waal H, Lutfalla G, Weissenbach J, Petit C: The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell 1991;67:423–435.
9.
Ballabio A, Parenti G, Tippett P, Mondello C, Di Maio S, Tenore A, Andria G: X-linked ichthyosis due to steroid sulphatase deficiency associated with Kallmann syndrome (hypogonadotropic hypogonadism and anosmia): Linkage relationships with Xg and cloned DNA sequences from the distal short arm of the X chromosome. Hum Genet 1986;72:237–240.
10.
Hardelin J-P, Levilliers J, del Castillo I, Cohen-Salmon M, Legouis R, Blanchard S, Compain S, Bouloux P-MG, Kirk JMW, Moraine C, Chaussain JL, Weissenbach J, Petit C: X chromosome-linked Kallmann syndrome: Stop mutations validate the candidate gene. Proc Natl Acad Sci USA 1992;89:8190–8194.
11.
del Castillo I, Cohen-Salmon M, Blanchard S, Lutfalla G, Petit C: Structure of the X-linked Kallmann syndrome gene and its homologous pseudogene on the Y chromosome. Nat Genet 1992;2:305–310.
12.
Soussi-Yanicostas N, Hardelin J-P, Arroyo-Jimenez MM, Ardouin O, Legouis R, Levilliers J, Traincard F, Betton JM, Cabanie L, Petit C: Initial characterization of anosmin-1, a putative extracellular matrix protein synthesized by definite neuronal cell populations in the central nervous system. J Cell Sci 1996;109:1749–1757.
13.
Rugarli EI, Lutz B, Kuratani SC, Wawersik S, Borsani G, Ballabio A, Eichele G: Expression pattern of the Kallmann syndrome gene in the olfactory system suggests a role in neuronal targeting. Nat Genet 1993;4:19–26.
14.
Hardelin J-P, Julliard AK, Moniot B, Soussi-Yanicostas N, Verney C, Schwanzel-Fukuda M, Ayer-Le Lievre C, Petit C: Anosmin-1 is a regionally restricted component of basement membranes and interstitial matrices during organogenesis: Implications for the developmental anomalies of X chromosome-linked Kallmann syndrome. Dev Dyn 1999;215:26–44.
15.
Schwanzel-Fukuda M, Bick D, Pfaff DW: Lu- teinizing hormone-releasing hormone (LHRH)- expressing cells do not migrate normally in an inherited hypogonadal (Kallmann) syndrome. Mol Brain Res 1989;6:311–326.
16.
Colquhoun-Kerr JS, Gu W-X, Jameson JL, Withers S, Bode HH: X-linked Kallmann syndrome and renal agenesis occurring together and independently in a large Australian family. Am J Med Genet 1999;83:23–27.
17.
Quinton R, Duke VM, de Zoysa PA, Platts AD, Valentine A, Kendall B, Pickman S, Kirk JMW, Besser GM, Jacobs HS, Bouloux P-MG: The neuroradiology of Kallmann’s syndrome: A gentoypic and phenotypic analysis. J Clin Endocrinol Metab 1996;81:3010–3017.
18.
Mayston MJ, Harrison LM, Quinton R, Stephens JA, Krams M, Bouloux P-MG: Mirror movements in X-linked Kallmann’s syndrome: A neurophysiological study. Brain 1997;120:1199–1216.
19.
Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: A Laboratory Manual, ed 2. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1989.
20.
Hardelin J-P, Levilliers J, Blanchard S, Carel J-C, Leutenegger M, Pinard-Bertelletto J-P, Bouloux P-MG, Petit C: Heterogeneity in the mutations responsible for X chromosome-linked Kallmann syndrome. Hum Mol Genet 1993;2:373–377.
21.
Wulfsberg EA, Curtis J, Jayne CH: Chondrodysplasia punctata: A boy with X-linked recessive chondrodysplasia punctata due to an inherited X-Y translocation with a current classification of these disorders. Am J Med Genet 1992;43:823–828.
22.
Maya-Núñez G, Zenteno JC, Ulloa-Aguirre A, Kofman-Alfaro S, Méndez JP: A recurrent missense mutation in the KAL gene in patients with X-linked Kallmann’s syndrome. J Clin Endocrinol Metab 1998;83:1650–1653.
23.
Gu W-X, Colquhoun-Kerr JS, Kopp P, Bode HH, Jameson JL: A novel aminoterminal mutation in the KAL-1 gene in a large pedigree with X-linked Kallmann syndrome. Mol Genet Metab 1998;65:59–61.
24.
Meitinger T, Heye B, Petit C, Levilliers J, Golla A, Moraine C, Dalla Piccola B, Sippell WG, Murken J, Ballabio A: Definitive localization of X-linked Kallmann syndrome (hypogonadotropic hypogonadism and anosmia) to Xp22.3: Close linkage to the hypervariable repeat sequence CRI-S232. Am J Hum Genet 1990;47:664–669.
25.
Chothia C, Jones EX: The molecular structure of cell adhesion molecules; in Richardson CC (ed): Annual Review of Biochemistry. Palo Alto, Annual Reviews, 1997, vol 66, pp 823–862.
26.
Kirk JMW, Grant DB, Besser GM, Shalet S, Quinton R, Smith CS, White M, Edwards O, Bouloux P-MG: Unilateral renal aplasia in X-linked Kallmann’s syndrome. Clin Genet 1994;46:260–262.
27.
Krams M, Quinton R, Ashburner J, Friston KJ, Frackowiak RSJ, Bouloux P-MG, Passingham RE: Mirror movements associated with bilateral corticospinal tract hypertrophy. Neurology 1999;52:816–822.
28.
Duke VM, Winyard PJD, Thorogood P, Soothill P, Bouloux P-MG, Woolf AS: KAL, a gene mutated in Kallmann’s syndrome, is expressed in the first trimester of human development. Mol Cell Endocrinol 1995;110:73–79.
29.
Hardelin J-P, Petit C: A moelcular approach to the pathophysiology of the X chromosome-linked Kallmann’s syndrome; in Thakker RV (ed): Baillière’s Clinical Endocrinology and Metabolism. London, Baillière Tindall, 1995, vol 9, pp 489–507.
30.
Dattani MT, Martinez-Barbera J-P, Thomas PQ, Brickman JM, Gupta R, Mårtensson I-L, Toresson H, Fox M, Wales JKH, Hindmarsch PC, Krauss S, Beddington RSP, Robinson ICAF: Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 1998;19:125–133.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.